Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lercanidipine
Drug ID BADD_D01255
Description Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Indications and Usage For the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
Marketing Status approved; investigational
ATC Code C08CA13
DrugBank ID DB00528
KEGG ID D08111
MeSH ID C060343
PubChem ID 65866
TTD Drug ID D0P6ZH
NDC Product Code Not Available
UNII V7XTJ4R0BH
Synonyms lercanidipine | methyl-1,1-dimethyl-2-(N-(3,3-diphenylpropyl)-N-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | lercanidipine hydrochloride | Zanidip | Lerdip | Lercadip | REC 15-2375 | REC-15-2375
Chemical Information
Molecular Formula C36H41N3O6
CAS Registry Number 100427-26-7
SMILES CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+ ](=O)[O-])C(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic failure09.01.03.002--
Hepatitis09.01.07.004--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.001--
Hypersensitivity10.01.03.003--
Hypertriglyceridaemia14.08.02.001--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Ileus07.13.01.001--
Immune system disorder10.02.01.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Laryngeal pain22.12.03.010--
Leukocytosis01.02.01.002--
Liver disorder09.01.08.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Lung infiltration22.01.02.004--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Migraine24.03.05.003; 17.14.02.001--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Myositis15.05.01.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages